RenovoRx, Inc. (RNXT)
1.26
-0.02
(-1.56%)
USD |
NASDAQ |
Oct 12, 10:55
RenovoRx EPS Diluted (Quarterly) : -0.0616 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0616 |
| March 31, 2026 | -0.0926 |
| December 31, 2025 | -0.0803 |
| September 30, 2025 | -0.0795 |
| June 30, 2025 | -0.0792 |
| March 31, 2025 | -0.0771 |
| December 31, 2024 | -0.1197 |
| September 30, 2024 | -0.0991 |
| June 30, 2024 | -0.0993 |
| March 31, 2024 | -0.072 |
| December 31, 2023 | -0.3018 |
| September 30, 2023 | -0.1329 |
| June 30, 2023 | -0.2184 |
| Date | Value |
|---|---|
| March 31, 2023 | -0.3583 |
| December 31, 2022 | -0.237 |
| September 30, 2022 | -0.2356 |
| June 30, 2022 | -0.2864 |
| March 31, 2022 | -0.334 |
| December 31, 2021 | -0.2636 |
| September 30, 2021 | -0.1696 |
| June 30, 2021 | -0.1512 |
| March 31, 2021 | -0.1325 |
| September 30, 2020 | -0.123 |
| June 30, 2020 | -0.0892 |
| March 31, 2020 | -0.1213 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Enanta Pharmaceuticals, Inc. | -0.6704 |
| Travere Therapeutics, Inc. | -0.3722 |
| REGENXBIO, Inc. | 0.4283 |
| Krystal Biotech, Inc. | 1.786 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.911M |
| Revenue (Quarterly) | 0.909M |
| Total Expenses (Quarterly) | 3.82M |
| Enterprise Value | 48.67M |
| Gross Profit Margin (Quarterly) | 84.27% |
| Profit Margin (Quarterly) | -320.2% |
| Earnings Yield | -24.92% |
| Normalized Earnings Yield | -26.21 |